Arlington Trust Co LLC Has $938,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Arlington Trust Co LLC boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 5,092.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 12,306 shares of the medical research company's stock after purchasing an additional 12,069 shares during the period. Arlington Trust Co LLC's holdings in Edwards Lifesciences were worth $938,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company's stock valued at $3,577,163,000 after acquiring an additional 325,808 shares in the last quarter. State Street Corp boosted its holdings in shares of Edwards Lifesciences by 0.4% in the second quarter. State Street Corp now owns 27,053,304 shares of the medical research company's stock valued at $2,551,938,000 after acquiring an additional 108,102 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Edwards Lifesciences by 0.3% in the second quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company's stock valued at $1,934,919,000 after acquiring an additional 66,763 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company's stock valued at $1,138,575,000 after acquiring an additional 1,390,427 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 104,971.3% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company's stock valued at $1,148,938,000 after acquiring an additional 15,384,593 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent analyst reports. OTR Global upgraded shares of Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research note on Tuesday, March 26th. Citigroup raised their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a research note on Wednesday. Evercore ISI raised their price objective on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an "in-line" rating in a research note on Thursday. Mizuho raised their price objective on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the company a "buy" rating in a research note on Wednesday, February 7th. Finally, Oppenheimer raised their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an "outperform" rating in a research note on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $90.67.

Edwards Lifesciences Trading Up 1.6 %

Edwards Lifesciences stock traded up $1.50 during trading on Friday, reaching $92.70. The company had a trading volume of 2,561,359 shares, compared to its average volume of 3,581,903. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The stock's 50 day moving average price is $88.67 and its two-hundred day moving average price is $77.02. The firm has a market capitalization of $55.80 billion, a price-to-earnings ratio of 40.30, a PEG ratio of 4.59 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the previous year, the firm earned $0.64 earnings per share. Edwards Lifesciences's revenue for the quarter was up 13.3% on a year-over-year basis. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michael A. Mussallem sold 29,350 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now directly owns 4,486 shares of the company's stock, valued at $388,801.62. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Michael A. Mussallem sold 29,350 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now directly owns 4,486 shares of the company's stock, valued at $388,801.62. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 10,000 shares of the business's stock in a transaction on Friday, January 12th. The stock was sold at an average price of $75.67, for a total transaction of $756,700.00. Following the transaction, the vice president now directly owns 39,503 shares in the company, valued at $2,989,192.01. The disclosure for this sale can be found here. Insiders sold a total of 189,604 shares of company stock worth $16,593,546 over the last ninety days. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.